Paper · 35514744
Building Block Analysis of ATIII Affinity Fractions of Heparins: Application to the ATIII Binding Capacity of Non-conventional 3-O-Sulfated Sequences.
Mourier P. Front Med (Lausanne), 2022. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Building Block Analysis of ATIII Affinity Fractions of Heparins: Application to the ATIII Binding Capacity of Non-conventional 3-O-Sulfated Sequences. Papers, record 35514744. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35514744
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Building Block Analysis of ATIII Affinity Fractions of Heparins: Application to the ATIII Binding Capacity of Non-conventional 3-O-Sulfated Sequences.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26,280,926 | Analytical and statistical comparability of generic enoxaparins from the US market with the originator product. | J Pharm Biomed Anal | 2015 | https://conductscience.org/library/papers/26280926 | PubMed |
| 2 | 32,515,841 | Degeneracy of the Antithrombin Binding Sequence in Heparin: 2-O-Sulfated Iduronic Acid Can Replace the Critical Glucuronic Acid. | Chemistry | 2020 | https://conductscience.org/library/papers/32515841 | PubMed |
| 3 | 28,340,300 | Synthesis of 3-O-Sulfated Oligosaccharides to Understand the Relationship between Structures and Functions of Heparan Sulfate. | J Am Chem Soc | 2017 | https://conductscience.org/library/papers/28340300 | PubMed |
| 4 | 28,282,887 | New Insights in Thrombin Inhibition Structure-Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin. | Molecules | 2017 | https://conductscience.org/library/papers/28282887 | PubMed |
| 5 | 27,497,655 | Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components. | J Pharm Biomed Anal | 2016 | https://conductscience.org/library/papers/27497655 | PubMed |
| 6 | 25,019,497 | Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. | Drug Discov Today | 2014 | https://conductscience.org/library/papers/25019497 | PubMed |
| 7 | 1,278,445 | Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. | FEBS Lett | 1976 | https://conductscience.org/library/papers/1278445 | PubMed |
| 8 | 28,671,597 | Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate. | Pharmaceuticals (Basel) | 2017 | https://conductscience.org/library/papers/28671597 | PubMed |
| 9 | 23,083,208 | An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence. | Biochem J | 2013 | https://conductscience.org/library/papers/23083208 | PubMed |
| 10 | 35,433,769 | Heparinase Digestion of 3-O-Sulfated Sequences: Selective Heparinase II Digestion for Separation and Identification of Binding Sequences Present in ATIII Affinity Fractions of Bovine Intestinal Heparins. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35433769 | PubMed |
1 to 10 of 15
See all 15 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,509,818 | The Content and Location of 3-O-Sulfated Glucosamine Enable Differentiation of Ovine, Bovine and Porcine Heparins. | Biomolecules | 2026 | https://conductscience.org/library/papers/42509818 | PubMed |
| 36,559,171 | Thrombin and Factor Xa Hydrolysis of Chromogenic Substrates in the Presence of Sulfated Derivatives of Galactomannan and Galactoglucomannan Natural Gels. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559171 | PubMed |
| 35,433,769 | Heparinase Digestion of 3-O-Sulfated Sequences: Selective Heparinase II Digestion for Separation and Identification of Binding Sequences Present in ATIII Affinity Fractions of Bovine Intestinal Heparins. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35433769 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SERPINC1 | 462 | PubTator's text mining | https://conductscience.org/library/genes/462 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35514744
GET https://conductscience.org/api/papers/v1/35514744/authors